Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan delivers ‘very strong’ first quarter performance

Allergan delivers ‘very strong’ first quarter performance

6th May 2011

Allergan has published its financial report for the first quarter of 2011, during which it experienced a double-digit year-on-year growth in sales.

The company's net sales total for the quarter was $1.25 billion (763.04 million), up by 13.3 percent on Q1 2010, with both its specialty pharmaceutical and medical device business units seeing growth.

This was thanks in part to the launch of several new products and indications ratified for sale in 2010, which was a record year of approvals for the company.

For the 2011 full-year period, the firm has therefore adjusted its expectations and is now estimating an annual net product sales total of between $5.05 billion and $5.25 billion.

David Pyott, Allergan's chairman of the board, president and chief executive officer, said: "During the first quarter, Allergan delivered very strong growth in sales and operating results."

Last month, Allergan received a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for its biodegradable implant Ozurdex to be utilised as a non-infectious uveitis therapy, based on positive phase III trial data.ADNFCR-8000103-ID-800521904-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.